![]() |
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3
Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by...
More... |
| All times are GMT -7. The time now is 08:10 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021